

VU Research Portal

Secondary Prevention for Alzheimer Disease

Vermunt, L.

2020

document version

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

citation for published version (APA)

Vermunt, L. (2020). *Secondary Prevention for Alzheimer Disease: Timing, Selection, and Endpoint of Clinical Trials*. [PhD-Thesis - Research and graduation internal, Vrije Universiteit Amsterdam].

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl

CONTENTS

Chapter 1	General introduction	7
Chapter 2	Clinical course of Alzheimer disease	19
2.1	Duration of preclinical, prodromal, and dementia stages of Alzheimer disease in relation to age, sex, and <i>APOE</i> genotype.	19
2.2	Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal.	63
Chapter 3	Recruitment for Alzheimer disease research	81
3.1	European prevention of Alzheimer dementia (EPAD) Registry: recruitment and pre-screening approach for a longitudinal cohort and prevention trials.	81
3.2	Prescreening for European Prevention of Alzheimer Dementia (EPAD) Trial-Ready Cohort: Impact of AD risk factors and recruitment settings.	91
Chapter 4	Grey matter networks, a potential endpoint for trials	111
4.1	Grey matter networks decline over the disease course of autosomal dominant Alzheimer disease.	111
4.2	Biological correlates of grey matter network disruption in Alzheimer disease.	140
Chapter 5	Summary and general discussion	157
Appendix		171
	List of publications	171
	List of PhD theses of Alzheimer Center Amsterdam	173
	List of abbreviations	175
	Nederlandstalige samenvatting	176
	Dankwoord	183
	Nederlandstalige blogs voor algemene publiek	185
	About the author	192